within Pharmacolibrary.Drugs.ATC.R;

model R07AX02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.0002883333333333333,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.273,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.111,
    k12             = 13.7,
    k21             = 13.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R07AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, approved for use in patients with cystic fibrosis who have specific genetic mutations (such as G551D) that respond to this therapy. It is an oral drug used to improve lung function and reduce symptoms in affected individuals. Ivacaftor is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers and cystic fibrosis patients (both sexes, age range: adolescent to adult) after oral administration. Data summarized from published literature and regulatory submission.</p><h4>References</h4><ol><li><p>Pozniak, J, et al., &amp; Slanař, O (2024). Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats. <i>Frontiers in pharmacology</i> 15 1331637–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2024.1331637\">10.3389/fphar.2024.1331637</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38444938/\">https://pubmed.ncbi.nlm.nih.gov/38444938</a></p></li><li><p>Wainwright, CE (2014). Ivacaftor for patients with cystic fibrosis. <i>Expert review of respiratory medicine</i> 8(5) 533–538. DOI:<a href=\"https://doi.org/10.1586/17476348.2014.951333\">10.1586/17476348.2014.951333</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25148205/\">https://pubmed.ncbi.nlm.nih.gov/25148205</a></p></li><li><p>Nakhla, DS, et al., &amp; Salem, AK (2025). Cyclodextrin-Based Inclusion Complexes Improve the In Vitro Solubility and Pharmacokinetics of Ivacaftor Following Oral Administration in Mice. <i>AAPS PharmSciTech</i> 26(5) 135–None. DOI:<a href=\"https://doi.org/10.1208/s12249-025-03131-6\">10.1208/s12249-025-03131-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40379997/\">https://pubmed.ncbi.nlm.nih.gov/40379997</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R07AX02;
